AVII: Summary for AVI BioPharma, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 8:10am EST - Canadian Markets open in 1 hour and 20 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

AVI Biopharma, Inc. (AVII)

On Nov 24: 1.49 USD 0.00 (0.00%)

MORE ON AVII

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

AVI BioPharma, Inc. (NGM:AVII) Delayed quote data

Last Trade:	1.49 USD
Trade Time:	Nov 24
Change:	0.00 (0.00%)
Prev Close:	1.49
Open:	N/A
Bid:	1.40 x 2000
Ask:	1.59 x 700
1y Target Est:	3.50

Day's Range:	N/A - N/A
52wk Range:	0.46 - 2.73
Volume:	0
Avg Vol (3m):	3,490,120
Market Cap:	164.55M
P/E (ttm):	N/A
EPS (ttm):	-0.55
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add AVII to Portfolio

Download Data

HEADLINES

•	AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference
	Marketwire (Thu, Nov 19)

•	AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day
	Marketwire (Wed, Nov 18)

•	AVI BIOPHARMA INC Financials
	EDGAR Online Financials (Fri, Nov 13)

•	AVI BioPharma loses $8.1M in Q3
	at bizjournals.com (Mon, Nov 9)

•	AVI BioPharma Announces Third Quarter 2009 Financial Results & Corporate Highlights
	Marketwire (Mon, Nov 9)

•	Q3 2009 AVI BioPharma Earnings Release - Time Not Supplied
	CCBN (Mon, Nov 9)

•	AVI BIOPHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit
	EDGAR Online (Mon, Nov 9)

•	AVI BioPharma Announces Third Quarter 2009 Financial Results Conference Call
	Marketwire (Mon, Nov 2)

•	AVI BioPharma Presents Updated Safety Data From Ongoing Systemic Trial of AVI-4658 at 7th Annual Action Duchenne International Conference
	Marketwire (Mon, Oct 26)

•	4-Star Stocks on the Upswing
	at Motley Fool (Fri, Oct 23)

More Headlines for AVII...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	1.5
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

AVI BioPharma, Inc., a biopharmaceutical company, develops therapeutic products for the treatment of life-threatening diseases using NeuGene antisense drugs and ESPRIT exon skipping technology.

Full Company Profile

Add to Portfolio

Email to a Friend

•